The central question is whether SOPHiA GENETICS SA (SOPH) can climb to a $10 stock price target, roughly 25% above recent trading levels. Bullish drivers include accelerating revenue growth, raised full-year guidance, expanding U.S. traction, and high-profile companion-diagnostics partnerships.
TEM shares surged +10.67% during regular trading, climbing from a prior close of $62.21 to about $68.85. The rally followed Piper Sandler's upgrade to Overweight with a raised $76 price target, citing the Personalis acquisition, positive INTerpath-001 trial data, and FDA clearance of the xT CDx test.
Selected price target: $80 per share, a level cited by multiple Wall Street firms including Cantor Fitzgerald, BTIG, Canaccord Genuity, and Raymond James. Strongest bullish factors: accelerating revenue growth, a first quarter of GAAP profitability, FDA approval for a key diagnostic, and the pending Personalis acquisition.
Omada Health shares fell roughly -7.86% during regular trading, dropping from a $21.50 prior close to about $19.81. The decline follows the company's inaugural Investor Day on Sept. 10, where new long-term targets (80% non-GAAP gross margin, 30% adjusted EBITDA margin) failed to satisfy investors, triggering a "sell-the-news" reaction.
DOCS closed up +2.15% (+$0.52) to $24.71 in Wednesday's regular session, rebounding from the prior close of $24.19. The gain was a technical rebound and bargain-buying after shares fell roughly -7% earlier in the week following a downgrade to Hold.
PHR is trading down -8.61% to $10.83, after closing the prior session at $11.85, with the decline gapping down in premarket and continuing during regular hours. The primary catalyst was a Q2 FY2027 earnings miss: adjusted EPS of $0.03 fell short of the $0.09 consensus, overshadowing revenue of $129.5M that slightly beat estimates.
Tempus AI shares rose roughly 70% over the last 30 days, climbing from about $41.55 on July 29, 2026, to $70.69 on August 27, 2026. The sharpest move came after a Phase 3 melanoma win from Merck and Moderna validated Tempus's pending $1.5 billion acquisition of Personalis.
VEEV surged +19.63% to roughly $292.98 during regular trading, building on a strong post-earnings reaction. The rally followed fiscal Q2 results: revenue rose +17.6% year over year to $927.96 million, above the ~$905 million consensus.
HQY is down -11.32% to $92.60 in regular trading, extending a roughly -7.6% premarket slide after results hit before the open. Catalyst: Q2 FY2027 earnings merely met elevated expectations — revenue +8% YoY to $350.7M and non-GAAP EPS $1.24 versus a $1.19 consensus.
HeartFlow shares rose approximately 92.9% over the trailing 30 days, climbing from about $25.37 to roughly $48.94. The rally was driven by second-quarter 2026 results that beat expectations and a meaningful increase to full-year revenue guidance.
SOPH rose +3.84% to close at $8.65 in the latest completed session, up +$0.32 from the prior close of $8.33. The move occurred during regular market hours, extending a rally that carried shares to a fresh 52-week high (intraday high $8.68).
The selected target: $100 per share, a round-number psychological milestone roughly 56% above recent trading levels. Strongest bullish factor: Accelerating adoption of the Atera platform, a 74% gross margin, and raised 2026 revenue guidance of $610–$630 million.
10x Genomics (TXG) shares climbed roughly 35.7% over the trailing 30 days, rising from a closing price of $47.05 to about $63.87. The advance was powered by a stronger-than-expected Q2 2026 report, an upward revision to full-year revenue guidance, and early enthusiasm for the new Atera spatial biology platform.
WEAV shares climbed +31.83% to $7.29 during regular trading, versus a prior-session close of $5.53. The intraday surge followed Weave's announcement of a definitive agreement to be acquired by Francisco Partners.
HeartFlow shares rose about 54.4% in the 30 days through the August 14, 2026 close, from $27.25 on July 15 to $42.08. The advance was led by second-quarter results: revenue of $64.1 million, up roughly 48% year over year, and an adjusted loss of $0.07 per share that beat consensus expectations for a wider loss.
HeartFlow shares are up +25.64% in regular trading Friday at $38.96, versus the prior close of $31.01. The move extends an after-hours surge following Q2 results: revenue rose +48% year-over-year to $64.1 million, beating forecasts, and adjusted loss per share of -$0.07 was much narrower than expected.
Waystar shares have gained approximately 8% over the last 30 days, rebounding from a mid-July dip and climbing above the $24 level following strong second-quarter results. Q2 2026 revenue reached $320 million, up 18% year-over-year, while adjusted EBITDA of $137 million exceeded Wall Street expectations.
Price target: $60 per share — representing roughly 15% upside from TXG's last close of $52.03, and aligning with the high end of recently raised analyst forecasts. Strongest bullish factor: The launch of the Atera spatial biology platform has generated extraordinary early demand, with booked orders already exceeding manufacturing capacity for 2026.
CERT closed at $7.80 on Tuesday, down -4.65% from $8.18, after an extreme intraday swing from a low of $6.33 to a high of $7.83 on heavy volume of 10.8M shares. The move followed a steep premarket gap down of nearly -19% after Q2 2026 earnings were released before the open, with the stock recovering substantially during the regular session.
WAY plunged -16.03% during regular trading on July 30, extending an after-hours drop of -5.38% that began following its Q2 2026 earnings release after the July 29 close. The selloff came despite a headline beat — EPS of $0.43 vs. $0.40 expected and revenue of $319.7M vs. $316.2M — and raised full-year 2026 guidance for both revenue and adjusted EBITDA.